Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?
Conclusions: Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.
PMID: 30151004 [PubMed]
Source: Advances in Urology - Category: Urology & Nephrology Tags: Adv Urol Source Type: research
More News: Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Oxybutynin | Statistics | Study | Urology & Nephrology | Women